How Have Bristol-Myers Squibb’s Revenues, Expenses & Profits Changed Over The Last Five Years?

+26.78%
Upside
51.59
Market
65.41
Trefis
BMY: Bristol Myers Squibb logo
BMY
Bristol Myers Squibb

We have created an interactive dashboard which looks at how Bristol-Myers Squibb’s (NYSE:BMY) revenues, expenses, and profits have changed over the last five years, as well as our forecasts for 2018. You can adjust the expected segment-wise revenue and margin forecast for 2018, and see its impact on the profitability, and earnings.

Change In Revenues By Division Between 2013 and 2017
  • The overall revenues increased by $4 billion over the last five years. This can be attributed to a significant ramp up in oncology drugs and cardiovascular drugs sales.

Change In Operating Expenses By Division Between 2013 and 2017

  • Operating expenses have increased by $1.6 billion over the last five years. This can be attributed to the oncology and cardiovascular segments, which saw an uptick in revenues during the period.
Relevant Articles
  1. Should You Pick Bristol Myers Squibb Stock After A 30% Fall Last Year And Q4 Beat?
  2. Is Bristol Myers Squibb Stock Undervalued At $50?
  3. Will Bristol Myers Squibb Stock Rebound To Its Pre-Inflation Shock Level of $80?
  4. Which Stock Is A Better Healthcare Pick – Bristol Myers Squibb Or HCA?
  5. Will Bristol Myers Squibb Stock Rise Post Q1?
  6. Is Bristol Myers Squibb Stock A Better Pick Over Its Industry Peer?

Change In Gross Profits By Division Between 2013 and 2017
  • The gross profit for the company increased by $2.8 billion over the last five years, led by oncology and cardiovascular drugs.

Trefis Estimates For 2018
  • We forecast BMY’s oncology drugs sales to grow in 2018 to around $9.3 billion led by a ramp up in Opdivo sales.
  • We also expect BMY’s Eliquis (in the cardiovascular segment) to continue to grow in the near term, as it is gaining market share. We estimate the segment sales to be around $5.2 billion in 2018.

Expect 2018 EPS To Be $3.2

  • We currently estimate the company’s EPS in 2018 to be $3.19, and our current price estimate for BMY is $60. You can adjust the Net Income to Gross Profit Ratio to arrive at your EPS estimate.

Our price estimate of $60 for Bristol Myers Squibb implies a discount of over 10% to the market.

What’s behind Trefis? See How it’s Powering New Collaboration and What-Ifs

For CFOs and Finance Teams | Product, R&D, and Marketing Teams

More Trefis Research

Like our charts? Explore example interactive dashboards and create your own